Competing interest
Cancer
CANCER
M.K. Bos received research funding from Dutch Cancer Society (no. NKB-EMCR-2016–108154), S.W. Lam: none, G. Motta: none, J.C.A. Helmijr: none, C.M. Beaufort: none, E. de Jonge: none, J.W.M. Martens received sponsorship for research from Pfizer, Menarini, GSK Cytotrack, Cergentis, payment for consultancy from Novartis, and payment for presentation from Roche, E. Boven: none, M.P.H.M. Jansen: none, A. Jager: none, and S. Sleijfer: none.
The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of all participating centers. Written informed consent was obtained before study enrollment. This trial is registered with the European Union Drug Regulating Authorities Clinical Trials, number 2006–006058-83, and the Netherlands Trial Register, number NTR1348.